To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Hepatitis C

Interventions

DRUG

DCV 3DAA FDC

DRUG

BMS-791325

Trial Locations (4)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology Of Miami Inc., Miami

New Orleans Center For Clinical Research - Knoxville, Knoxville

Davita Clinical Research, Minneapolis